Friday, December 8, 2023, 7:30 AM – 10:00 AM PT (10:30 AM – 1:00 PM ET)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 65th ASH Annual Meeting

Location
Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 10:00 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Stephen M Ansell, MD, PhD
Chair, Division of Hematology
Dorotha W and Grant L Sundquist Professor in
Hematologic Malignancies Research
Enterprise Deputy Director, Mayo Clinic Cancer Center
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota

Nancy L Bartlett, MD
Professor of Medicine
Koman Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri


Jonathon B Cohen, MD
Associate Professor, Hematology and Medical Oncology
Co-Director, Lymphoma Program
Emory University Winship Cancer Institute
Atlanta, Georgia

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck, and Seagen Inc.
Program Schedule — Pacific Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 10:00 AM — Educational Meeting

A detailed agenda will be available in the coming weeks.

MODULE 1: Evolving Role of Novel Treatment Strategies in Follicular Lymphoma (FL)

MODULE 2: Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapies and Bispecific Antibodies into the Management of FL

MODULE 3: Up-Front Treatment for Mantle Cell Lymphoma (MCL)

MODULE 4: Therapeutic Sequencing for Patients with R/R MCL

MODULE 5: First-Line Treatment Strategies for Hodgkin Lymphoma

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Evaluate the mechanism of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and determine the role of these agents in current clinical management.
  • Consider patient age, performance status and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL) to optimize therapy for patients with the disease.
  • Review available Phase III research findings with the use of Bruton tyrosine kinase (BTK) inhibitors as a component of induction therapy for MCL and assess the potential risks and benefits of this strategy in patients eligible and not eligible for autologous stem cell transplant.
  • Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors in patients with MCL, and use this information to evaluate the current role of these agents in individuals with R/R disease.
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess available clinical trial findings informing the utilization of CD19-directed CAR (chimeric antigen receptor) T-cell therapy for patients with R/R MCL and FL and counsel appropriately selected individuals regarding the potential benefits of this therapeutic strategy.
  • Recall new data with agents and strategies currently under investigation for FL, MCL and HL and consider the potential role these agents may soon play and ongoing trial opportunities available for eligible patients.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY— Faculty panel disclosures to be provided.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck, and Seagen Inc.

Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Meeting Room
Grand Ballroom (Level 2)

Directions
Located directly across from the San Diego Convention Center, where the 2023 ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.

There is no fee to participate in this hybrid event. For the in-person symposium in San Diego preregistration is required as seating is limited.

NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN PERSON Registration
for non-clinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.